A n 83-year-old male with a history of angina pectoris presented with massive intracranial hemorrhage in June 2011, and he died 2 days after admission. Previously, he was included in the first in-human feasibility study of biodegradable poly-l-lactic acid (PLLA) coronary stents: the Igaki-Tamai stents (Kyoto Medical Planning Co Ltd, Kyoto, Japan). 1, 2 To assess the long-term behavior of PLLA coronary stents in humans, postmortem examination of his coronary arteries was performed.
In November 1999, he was diagnosed with stable angina pectoris, and coronary angiography disclosed a single lesion at the middle part of left anterior descending coronary artery ( Figure 1A ). One Igaki-Tamai stent had been implanted with successful result ( Figure 1B) . He received follow-up coronary angiography at 6 months, which showed restenosis at the distal edge of the stent ( Figure 1C ). Because he was asymptomatic, reintervention was avoided. Additional coronary angiography at 2 and 6 years of follow-up revealed late lumen enlargement ( Figure 1D and 1E) .
The coronary arteries were examined histopathologically by hematoxylin and eosin staining and other histochemical methods. The spaces previously occupied by PLLA struts had disappeared, suggesting complete degradation of PLLA ( Figure 2A , 2D, and 2G). Inflammatory cell infiltration, foreign body reaction, and thrombus were not observed. The neointima consisted of connective tissue ( Figure 2B , 2E, and 2H) and smooth muscle cells ( Figure 2C , 2F, and 2I), and this stable neointimal layer sealed off old preexisting atherosclerotic plaques. The phenomenon of so-called neoatherosclerosis was not observed.
The Igaki-Tamai stent is the first in-human bioresorbable scaffold, and this is the first human histology case to show the complete biodegradation of PLLA. Although this is only a single case, the histological examination indicates the biocompatibility and the long-term safety of PLLA. This bioresorbable scaffold technology can be one of the ideal treatment choices for coronary artery disease, especially when viewed from a long-term standpoint.
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